Q32 Bio (QTTB) Net Cash Flow (QoQ) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Q32 Bio | 162.94 Mn | 112.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 430.73% |
| Dec 31, 2025 | 87.19% |
| Sep 30, 2025 | 45.61% |
| Jun 30, 2025 | 14.67% |
| Mar 31, 2025 | -12.32% |
| Dec 31, 2024 | -29.48% |
| Sep 30, 2024 | 51.91% |
| Jun 30, 2024 | -121.02% |
| Mar 31, 2024 | 897.93% |
| Dec 31, 2023 | -165.67% |
| Sep 30, 2023 | 242.72% |
| Jun 30, 2023 | 9.09% |
| Mar 31, 2023 | -36.07% |
| Dec 31, 2022 | 93.10% |
| Sep 30, 2022 | -84.21% |
| Jun 30, 2022 | -152.30% |
| Mar 31, 2022 | 943.44% |
| Dec 31, 2021 | 164.60% |
| Sep 30, 2021 | -272.18% |
| Jun 30, 2021 | 110.53% |
| Mar 31, 2021 | -386.64% |
| Dec 31, 2020 | 280.32% |
| Sep 30, 2020 | -57.27% |
| Jun 30, 2020 | -72.92% |
| Mar 31, 2020 | 476.70% |
| Dec 31, 2019 | 37.42% |
| Sep 30, 2019 | -150.86% |
| Jun 30, 2019 | 3,423.20% |
| Mar 31, 2019 | -1.99% |
| Dec 31, 2018 | 103.67% |
| Sep 30, 2018 | -220.83% |
| Jun 30, 2018 | 1,009.46% |
| Mar 31, 2018 | 88.39% |
| Dec 31, 2017 | -159.73% |
| Sep 30, 2017 | 1,374.42% |
| Jun 30, 2017 | -140.17% |